Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Veterinario de OncoLink / Tumores
Supported by the Savannah and Barry French Poodle Memorial Fund
University of Pennsylvania School of Veterinary Medicine
Ultima Vez Modificado: 21 de agosto del 2005
Michael H. Goldschmidt, MSc, BVMS, MRCVS, Diplomate ACVP Professor and Head, Laboratory of Pathology and Toxicology Chief, Surgical Pathology Department of Pathobiology
Frances S. Shofer, PhD, Adjunct Associate Professor of Epidemiology and Biostatistics
Apocrine glands have both a secretory and a ductal component. The secretion empties into the infundibulum of the hair follicle (epitrichial). The cells that make the secretion are columnar with copious granular eosinophilic cytoplasm and the nuclei are located in the base of the cell. The secretion is produced when the apical portion (top) of the cell is cleaved into the glandular lumen. The secretory cells are surrounded by myoepithelial cells which are surrounded by the basal lamina zone. The apocrine duct is lined by cuboidal epithelial cells that form a double layer.
Definition: A benign tumor with differentiation to apocrine secretory epithelium.
| Sex | N | Percent |
| Female |
278
|
17% (21%)
|
| Female Spayed |
574
|
35% (33%)
|
| Male |
463
|
28% (25%)
|
| Male Castrated |
331
|
20% (21%)
|
| (Normal Population %) |
| Breeds at Increased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Peekapoo |
15
|
<0.0001
|
4.7
|
2.8
|
7.8
|
| Alaskan Malamute |
11
|
0.0024
|
2.8
|
1.6
|
5.2
|
| Chow Chow |
17
|
0.0004
|
2.7
|
1.6
|
4.3
|
| Lhasa Apso |
45
|
<0.0001
|
2.6
|
1.9
|
3.5
|
| Old English Sheepdog |
20
|
0.0002
|
2.6
|
1.6
|
4.0
|
| Shih Tzu |
44
|
0.0003
|
1.8
|
1.4
|
2.5
|
| Collie |
23
|
0.0196
|
1.7
|
1.1
|
2.6
|
| Golden Retriever |
162
|
<0.0001
|
1.4
|
1.2
|
1.7
|
| Breeds at Decreased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Boxer |
19
|
<0.0001
|
0.39
|
0.25
|
0.62
|
| Miniature Schnauzer |
9
|
0.0011
|
0.38
|
0.20
|
0.73
|
| Doberman Pinscher |
13
|
<0.0001
|
0.28
|
0.16
|
0.48
|
| Boston Terrier |
2
|
0.0161
|
0.22
|
0.06
|
0.89
|
| Shar-Pei |
2
|
0.0059
|
0.20
|
0.05
|
0.79
|
| Pug |
1
|
0.0125
|
0.14
|
0.02
|
1.01
|
| Jack Russell Terrier |
1
|
0.0063
|
0.12
|
0.02
|
0.89
|
| Great Dane |
1
|
0.0003
|
0.09
|
0.01
|
0.61
|
| Apocrine Adenoma & Complex & Mixed Adenoma Site | Percent |
| Head | 21.7% |
| Neck | 19.4% |
| Forelimb | 14.6% |
| Hindlimb | 12.1% |
| Back | 7.2% |
| Abdomen | 7.0% |
| Thorax | 7.0% |
| Tail | 5.8% |
| Perineum | 3.4% |
| Multiple | 1.6% |
| Scrotum | 0.3% |

Three different histologic patterns may be found:
Surgical excision is curative, with no recurrence reported.
Definition: A benign tumor with differentiation to apocrine ductal epithelium.
| Sex | N | Percent |
| Female |
109
|
19% (21%)
|
| Female Spayed |
185
|
32% (33%)
|
| Male |
153
|
27% (25%)
|
| Male Castrated |
129
|
22% (21%)
|
| (Normal Population %) |
|
|
| Breeds at Increased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Old English Sheepdog |
14
|
<0.0001
|
5.2
|
3.0
|
8.8
|
| Bernese Mountain Dog |
5
|
0.0113
|
3.8
|
1.6
|
9.2
|
| Golden Retriever |
98
|
<0.0001
|
2.7
|
2.1
|
3.3
|
| English Springer Spaniel |
19
|
0.0036
|
2.1
|
1.3
|
3.4
|
| Breeds at Decreased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Doberman Pinscher |
6
|
0.0072
|
0.4
|
0.2
|
0.8
|
| Miniature Poodle |
5
|
0.0071
|
0.3
|
0.1
|
0.8
|
| Miniature Schnauzer |
2
|
0.0210
|
0.2
|
0.1
|
1.0
|
| Site | Percent |
| Head |
21.2%
|
| Forelimb |
15.4%
|
| Hindlimb |
14.1%
|
| Thorax |
11.1%
|
| Back |
10.7%
|
| Neck |
9.3%
|
| Abdomen |
8.4%
|
| Tail |
5.5%
|
| Perineum |
2.5%
|
| Multiple |
1.2%
|
| Scrotum |
0.6%
|

Surgical excision is curative, with no recurrence reported.
Definition:Complex (compound) apocrine tumors have glandular and myoepithelial cells. Mixed apocrine tumors show metaplastic change of the myoepithelium to cartilage or bone.
These are uncommon tumors. A histopathologic evaluation is required for a definitive diagnosis. The epithelial component must be evaluated to determine the malignant potential of these tumors.
| Sex | N | Percent |
| Female |
37
|
22% (21%)
|
| Female Spayed |
54
|
33% (33%)
|
| Male |
30
|
18% (25%)
|
| Male Castrated |
44
|
27% (21%)
|
| (Normal Population %) |
|
|
| Breeds at Increased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Lhasa Apso |
5
|
0.0354
|
2.8
|
1.2
|
6.9
|
| Cocker Spaniel |
14
|
0.0200
|
2.0
|
1.2
|
3.5
|
Note: Site distribution table for Complex and Mixed Apocrine Adenoma is included in the Apocrine Adenoma Site Distribution Table. Please see above.

Surgical excision is curative, with no recurrence reported.
Definition: A simple malignant tumor with differentiation to apocrine secretory epithelium.
| Sex | N | Percent |
| Female |
113
|
19% (21%)
|
| Female Spayed |
210
|
36% (33%)
|
| Male |
189
|
32% (25%)
|
| Male Castrated |
76
|
13% (21%)
|
| (Normal Population %) |
|
|
| Breeds at Increased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Norwegian Elkhound |
7
|
0.0002
|
6.0
|
2.8
|
12.6
|
| Chow Chow |
9
|
0.0006
|
4.0
|
2.1
|
7.7
|
| Old English Sheepdog |
9
|
0.0024
|
3.2
|
1.7
|
6.3
|
| German Shepherd |
52
|
<0.0001
|
2.3
|
1.7
|
3.0
|
| Shih Tzu |
19
|
0.0015
|
2.3
|
1.4
|
3.6
|
| Lhasa Apso |
12
|
0.0413
|
1.9
|
1.1
|
3.4
|
| Cocker Spaniel |
43
|
0.0012
|
1.7
|
1.3
|
2.4
|
| Mixed Breed |
186
|
<0.0001
|
1.5
|
1.3
|
1.8
|
| Breeds at Decreased Risk |
N | Probability | OR | 95% Confidence Interval |
|
| Boxer |
7
|
0.0123
|
0.4
|
0.2
|
0.9
|
| Rottweiler |
4
|
0.0070
|
0.3
|
0.1
|
0.8
|
| Miniature Schnauzer |
1
|
0.0044
|
0.1
|
0.0
|
0.8
|
| Apocrine Carcinoma & Ductal Carcinoma Site | Percent |
| Forelimb |
22.2%
|
| Hindlimb |
17.5%
|
| Head |
13.9%
|
| Abdomen |
11.4%
|
| Thorax |
9.7%
|
| Neck |
7.8%
|
| Tail |
6.5%
|
| Perineum |
6.0%
|
| Back |
4.1%
|
| Multiple |
0.8%
|
| Scrotum |
0.2%
|

Histopathology
Cytology
NOTE: Apocrine carcinomas are very similar histologically to mammary carcinomas.
Many of these tumors will metastasize to regional lymph nodes and possibly the lungs. Inflammatory apocrine carcinomas have been shown to do this most frequently, along with those carcinomas that are invasive and cause a desmoplastic response. Inflammatory apocrine carcinomas produce a diffuse interstitial pattern in the lung on radiographic evaluation. Small tumors that are removed soon after they are found, and well differentiated tumors, are usually cured via wide excision. Less well differentiated tumors will spread to regional lymph nodes and lungs.
Definition:A malignant tumor with differentiation to apocrine ductal epithelium.
These tumors are rare.
| Sex | N | Percent |
| Female |
25
|
27% (21%)
|
| Female Spayed |
29
|
32% (33%)
|
| Male |
21
|
23% (25%)
|
| Male Castrated |
17
|
18% (21%)
|
| (Normal Population %) |
|
|
Note: Site distribution table for Apocrine Ductal Carcinoma is included in the Apocrine Carcinoma Site Distribution Table. Please see above.

These tumors rarely recur after wide surgical excision. Metastases are very infrequently found.
Definition: Complex (compound) apocrine tumors have malignant proliferation of glandular cells and accompanying proliferation of myoepithelial cells. Mixed apocrine tumors show metaplastic change of the myoepithelium to cartilage or bone.
These are uncommon tumors. A histopathologic evaluation is required for a definitive diagnosis. The epithelial component must be evaluated to determine the malignant potential of these tumors.
(See apocrine carcinoma above)
Epithelial components will metastasize via lymphatics to the regional lymph nodes and lungs.
What every person should know about screening, learning about your disease and the importance of cllinical research. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

